23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › ARROWHEAD PHARMACEUTICALS INC. › 2023-2024

ARROWHEAD PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ARROWHEAD PHARMACEUTICALS INC.’s Form 8-K, filed March 19, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 9Reported items
  • 293Asset managers, any item
  • 2,979Fund votes
  • March 14, 2024Meeting date

Results at a glance

Meeting of March 14, 2024: 7 items on ARROWHEAD PHARMACEUTICALS INC.’s Form 8-K, filed March 19, 2024: 7 passed (calculated).

Dissent

Notable dissent: 1 director (12.6% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ARROWHEAD PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ARROWHEAD PHARMACEUTICALS INC.

These tallies are ARROWHEAD PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed March 19, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ARROWHEAD PHARMACEUTICALS INC. — official shareholder meeting results, meeting held March 14, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Douglass Given 76,397,56710,968,346303,938 ---- 87%Passed (calculated)—
Elect Director: Michael S. Perry 82,446,9004,911,855311,096 ---- 94%Passed (calculated)—
Elect Director: Christopher Anzalone 84,313,6962,976,660379,495 ---- 97%Passed (calculated)—
Elect Director: Mauro Ferrari 81,342,8846,020,799306,168 ---- 93%Passed (calculated)—
Elect Director: Adeoye Olukoton 83,526,8093,815,731327,311 ---- 96%Passed (calculated)—
Elect Director: William Waddill 83,279,6334,079,251310,967 ---- 95%Passed (calculated)—
Elect Director: Victoria Vakiener 83,354,9883,975,617339,246 ---- 95%Passed (calculated)—

Source: ARROWHEAD PHARMACEUTICALS INC., Form 8-K, filed with the SEC on March 19, 2024 — read the filing on EDGAR.

How asset managers voted at the ARROWHEAD PHARMACEUTICALS INC. 2023-2024 meeting

293 asset managers disclosed a vote on at least one ARROWHEAD PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ARROWHEAD PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Adeoye Olukoton

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 83,526,809AGAINST: 3,815,731
Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: Election of Directors: Adeoye Olukotun

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Adeoye Olukoton”): 83,526,809 for, 3,815,731 against, per its Form 8-K filed March 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 42,027,042 for, 135,480 against, 38,587 abstained.

FOR
FOR: 42,027,042AGAINST: 135,480ABSTAIN: 38,587
Largest asset managers voting on “Election of Directors: Adeoye Olukotun” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,801,2530 00For
BlackRock8,862,9940 00For
Fidelity8,258,1290 00For
State Street3,855,5500 00For
Capital Group1,533,0600 00For
JPMorgan1,422,4500 00For
Charles Schwab970,8770 00For
Columbia Threadneedle860,8180 00For
Equitable454,2850 00For
AIG/SunAmerica373,1420 00For
Jackson National369,8720 00For
TIAA327,6570 00For
T. Rowe Price325,1340 00For
MUTUAL FUND SERIES TRUST313,2890 00For
Dimensional280,7200 00For
Invesco216,0440 00For
Direxion Shares ETF Trust211,7120 00For
QUANTITATIVE MASTER SERIES LLC207,4400 00For
Voya176,8440 00For
Russell Investments172,8700 00For
Global X168,9340 00For
CARILLON SERIES TRUST156,6180 00For
Northern Trust141,1290 00For
Lincoln Financial135,2370 00For
John Hancock120,1800 00For

Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).

Elect Director: Christopher Anzalone

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 84,313,696AGAINST: 2,976,660
Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: Election of Directors: Christopher Anzalone

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Christopher Anzalone”): 84,313,696 for, 2,976,660 against, per its Form 8-K filed March 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 42,153,040 for, 9,482 against, 38,587 abstained.

FOR
FOR: 42,153,040AGAINST: 9,482ABSTAIN: 38,587
Largest asset managers voting on “Election of Directors: Christopher Anzalone” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,801,2530 00For
BlackRock8,862,9940 00For
Fidelity8,258,1290 00For
State Street3,855,5500 00For
Capital Group1,533,0600 00For
JPMorgan1,422,4500 00For
Charles Schwab970,8770 00For
Columbia Threadneedle860,8180 00For
Equitable454,2850 00For
AIG/SunAmerica373,1420 00For
Jackson National369,8720 00For
TIAA327,6570 00For
T. Rowe Price325,1340 00For
MUTUAL FUND SERIES TRUST313,2890 00For
Dimensional280,7200 00For
Invesco216,0440 00For
Direxion Shares ETF Trust211,7120 00For
QUANTITATIVE MASTER SERIES LLC207,4400 00For
Voya176,8440 00For
Russell Investments172,8700 00For
Global X168,9340 00For
CARILLON SERIES TRUST156,6180 00For
Northern Trust141,1290 00For
Lincoln Financial135,2370 00For
John Hancock120,1800 00For

Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).

Elect Director: Douglass Given

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 76,397,567AGAINST: 10,968,346
Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: Election of Directors: Douglass Given

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Douglass Given”): 76,397,567 for, 10,968,346 against, per its Form 8-K filed March 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 37,110,234 for, 5,052,288 against, 38,587 abstained.

FOR
FOR: 37,110,234AGAINST: 5,052,288ABSTAIN: 38,587
Largest asset managers voting on “Election of Directors: Douglass Given” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,801,2530 00For
BlackRock8,862,9940 00For
Fidelity8,258,1290 00For
State Street03,855,550 00Against
Capital Group1,533,0600 00For
JPMorgan1,422,4500 00For
Charles Schwab970,8770 00For
Columbia Threadneedle0860,818 00Against
Equitable454,2850 00For
AIG/SunAmerica373,1420 00For
Jackson National369,8720 00For
TIAA327,6570 00For
T. Rowe Price325,1340 00For
MUTUAL FUND SERIES TRUST313,2890 00For
Dimensional280,7200 00For
Invesco216,0440 00For
Direxion Shares ETF Trust211,7120 00For
QUANTITATIVE MASTER SERIES LLC207,4400 00For
Voya176,8440 00For
Russell Investments172,8700 00For
Global X168,9340 00For
CARILLON SERIES TRUST156,6180 00For
Northern Trust141,1290 00For
Lincoln Financial6,774128,463 00Mixed
John Hancock120,1800 00For

Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).

Elect Director: Mauro Ferrari

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 81,342,884AGAINST: 6,020,799
Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: Election of Directors: Mauro Ferrari

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mauro Ferrari”): 81,342,884 for, 6,020,799 against, per its Form 8-K filed March 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 41,577,417 for, 585,105 against, 38,587 abstained.

FOR
FOR: 41,577,417AGAINST: 585,105ABSTAIN: 38,587
Largest asset managers voting on “Election of Directors: Mauro Ferrari” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,801,2530 00For
BlackRock8,862,9940 00For
Fidelity8,258,1290 00For
State Street3,855,5500 00For
Capital Group1,533,0600 00For
JPMorgan1,422,4500 00For
Charles Schwab970,8770 00For
Columbia Threadneedle860,8180 00For
Equitable454,2850 00For
AIG/SunAmerica373,1420 00For
Jackson National369,8720 00For
TIAA327,6570 00For
T. Rowe Price325,1340 00For
MUTUAL FUND SERIES TRUST313,2890 00For
Dimensional280,7200 00For
Invesco216,0440 00For
Direxion Shares ETF Trust211,7120 00For
QUANTITATIVE MASTER SERIES LLC207,4400 00For
Voya176,8440 00For
Russell Investments172,8700 00For
Global X0168,934 00Against
CARILLON SERIES TRUST156,6180 00For
Northern Trust0141,129 00Against
Lincoln Financial135,2370 00For
John Hancock120,1800 00For

Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).

Elect Director: Michael S. Perry

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 82,446,900AGAINST: 4,911,855
Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: Election of Directors: Michael S. Perry

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Michael S. Perry”): 82,446,900 for, 4,911,855 against, per its Form 8-K filed March 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 42,028,875 for, 133,647 against, 38,587 abstained.

FOR
FOR: 42,028,875AGAINST: 133,647ABSTAIN: 38,587
Largest asset managers voting on “Election of Directors: Michael S. Perry” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,801,2530 00For
BlackRock8,862,9940 00For
Fidelity8,258,1290 00For
State Street3,855,5500 00For
Capital Group1,533,0600 00For
JPMorgan1,422,4500 00For
Charles Schwab970,8770 00For
Columbia Threadneedle860,8180 00For
Equitable454,2850 00For
AIG/SunAmerica373,1420 00For
Jackson National369,8720 00For
TIAA327,6570 00For
T. Rowe Price325,1340 00For
MUTUAL FUND SERIES TRUST313,2890 00For
Dimensional280,7200 00For
Invesco216,0440 00For
Direxion Shares ETF Trust211,7120 00For
QUANTITATIVE MASTER SERIES LLC207,4400 00For
Voya176,8440 00For
Russell Investments172,8700 00For
Global X168,9340 00For
CARILLON SERIES TRUST156,6180 00For
Northern Trust141,1290 00For
Lincoln Financial135,2370 00For
John Hancock120,1800 00For

Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).

Elect Director: Victoria Vakiener

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 83,354,988AGAINST: 3,975,617
Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: Election of Directors: Victoria Vakiener

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Victoria Vakiener”): 83,354,988 for, 3,975,617 against, per its Form 8-K filed March 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 41,746,322 for, 414,041 against, 40,746 abstained.

FOR
FOR: 41,746,322AGAINST: 414,041ABSTAIN: 40,746
Largest asset managers voting on “Election of Directors: Victoria Vakiener” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,801,2530 00For
BlackRock8,862,9940 00For
Fidelity8,258,1290 00For
State Street3,855,5500 00For
Capital Group1,533,0600 00For
JPMorgan1,422,4500 00For
Charles Schwab970,8770 00For
Columbia Threadneedle860,8180 00For
Equitable454,2850 00For
AIG/SunAmerica373,1420 00For
Jackson National369,8720 00For
TIAA327,6570 00For
T. Rowe Price325,1340 00For
MUTUAL FUND SERIES TRUST313,2890 00For
Dimensional0280,720 00Against
Invesco216,0440 00For
Direxion Shares ETF Trust211,7120 00For
QUANTITATIVE MASTER SERIES LLC207,4400 00For
Voya176,8440 00For
Russell Investments172,8700 00For
Global X168,9340 00For
CARILLON SERIES TRUST156,6180 00For
Northern Trust141,1290 00For
Lincoln Financial135,2370 00For
John Hancock120,1800 00For

Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).

Elect Director: William Waddill

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 83,279,633AGAINST: 4,079,251
Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: Election of Directors: William Waddill

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: William Waddill”): 83,279,633 for, 4,079,251 against, per its Form 8-K filed March 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 42,028,875 for, 133,647 against, 38,587 abstained.

FOR
FOR: 42,028,875AGAINST: 133,647ABSTAIN: 38,587
Largest asset managers voting on “Election of Directors: William Waddill” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,801,2530 00For
BlackRock8,862,9940 00For
Fidelity8,258,1290 00For
State Street3,855,5500 00For
Capital Group1,533,0600 00For
JPMorgan1,422,4500 00For
Charles Schwab970,8770 00For
Columbia Threadneedle860,8180 00For
Equitable454,2850 00For
AIG/SunAmerica373,1420 00For
Jackson National369,8720 00For
TIAA327,6570 00For
T. Rowe Price325,1340 00For
MUTUAL FUND SERIES TRUST313,2890 00For
Dimensional280,7200 00For
Invesco216,0440 00For
Direxion Shares ETF Trust211,7120 00For
QUANTITATIVE MASTER SERIES LLC207,4400 00For
Voya176,8440 00For
Russell Investments172,8700 00For
Global X168,9340 00For
CARILLON SERIES TRUST156,6180 00For
Northern Trust141,1290 00For
Lincoln Financial135,2370 00For
John Hancock120,1800 00For

Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).

Advisory vote to approve executive compensation.

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

98% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 289 asset managers

Description as filed by funds: ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 79 asset managers voting on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,801,2530 00For
BlackRock8,862,9940 00For
Fidelity8,258,1290 00For
State Street3,855,5500 00For
Capital Group1,533,0600 00For
JPMorgan1,422,4500 00For
Charles Schwab970,8770 00For
Columbia Threadneedle860,8180 00For
Equitable454,2850 00For
AIG/SunAmerica373,1420 00For
Jackson National369,8720 00For
TIAA327,6570 00For
T. Rowe Price325,1340 00For
MUTUAL FUND SERIES TRUST313,2890 00For
Dimensional280,7200 00For
Invesco216,0440 00For
Direxion Shares ETF Trust211,7120 00For
QUANTITATIVE MASTER SERIES LLC207,4400 00For
Voya176,8440 00For
Russell Investments172,8700 00For
Global X168,9340 00For
CARILLON SERIES TRUST156,6180 00For
Northern Trust141,1290 00For
Lincoln Financial135,2370 00For
John Hancock120,1800 00For

Fund voting reports, all 79 managers: 42,105,703 for, 766 against, 38,587 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 237 asset managers voting on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Lazard19,000,0000 00For
Avoro Capital Advisors LLC6,983,6300 00For
State Street6,622,1790 00For
Fidelity6,352,1160 00For
BlackRock3,916,239539 00For
GEODE CAPITAL MANAGEMENT, LLC2,634,9550 00For
UBS1,651,0470 00For
Capital Group1,533,0600 00For
Slate Path Capital LP1,416,9910 00For
MELLON INVESTMENTS Corp1,287,2070 00For
Avidity Partners Management LP1,184,5240 00For
Charles Schwab970,8770 00For
Aquilo Capital Management, LLC00 0908,474Withhold
ORBIMED ADVISORS LLC739,6510 00For
PICTET ASSET MANAGEMENT SA624,0000 00For
T. Rowe Price481,2080 00For
PRINCIPAL GLOBAL INVESTORS470,0380 00For
Citadel427,9620 00For
First Light Asset Management, LLC425,9630 00For
Nuveen362,8570 00For
Vanguard343,7840 00For
EAGLE ASSET MANAGEMENT INC323,4950 00For
JPMorgan281,2920 00For
Invesco262,6930 00For
AllianceBernstein225,2040 00For

Institutional-manager reports, all 237 managers: 63,076,918 for, 734,422 against, 908,474 withheld, 11 abstained. Showing the 25 largest; every one is in the interactive database (link above).

To ratify the selection of KPMG LLP as independent auditors of the company for the fiscal year ending September 30…

No official matchAUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR
Details: description as filed, votes by 79 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF KPMG LLP AS INDEPENDENT AUDITORS OF THE COMPANY FOR THE FISCAL YEAR ENDING SEPTEMBER 30, 2024.

The 79 asset managers below reported 42,106,469 for, 38,587 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 42,106,469ABSTAIN: 38,587
Largest asset managers voting on “TO RATIFY THE SELECTION OF KPMG LLP AS INDEPENDENT AUDITORS OF THE COMPANY FOR THE FISCAL YEAR ENDING SEPTEMBE” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,801,2530 00For
BlackRock8,862,9940 00For
Fidelity8,258,1290 00For
State Street3,855,5500 00For
Capital Group1,533,0600 00For
JPMorgan1,422,4500 00For
Charles Schwab970,8770 00For
Columbia Threadneedle860,8180 00For
Equitable454,2850 00For
AIG/SunAmerica373,1420 00For
Jackson National369,8720 00For
TIAA327,6570 00For
T. Rowe Price325,1340 00For
MUTUAL FUND SERIES TRUST313,2890 00For
Dimensional280,7200 00For
Invesco216,0440 00For
Direxion Shares ETF Trust211,7120 00For
QUANTITATIVE MASTER SERIES LLC207,4400 00For
Voya176,8440 00For
Russell Investments172,8700 00For
Global X168,9340 00For
CARILLON SERIES TRUST156,6180 00For
Northern Trust141,1290 00For
Lincoln Financial135,2370 00For
John Hancock120,1800 00For

Showing the 25 largest of 79 asset managers. All 79 are in the interactive database (link above).

Largest ARROWHEAD PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 107,500,000 shares outstanding at the time of that meeting.

Fund voting reports: top ARROWHEAD PHARMACEUTICALS INC. shareholders by shares voted on “Election of Directors: Adeoye Olukotun”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 10.05%
2BlackRock 8.24%
3Fidelity 7.68%
4State Street 3.59%
5Capital Group 1.43%
6JPMorgan 1.32%
7Charles Schwab 0.90%
8Columbia Threadneedle 0.80%
9Equitable 0.42%
10AIG/SunAmerica 0.35%
Institutional-manager reports: top ARROWHEAD PHARMACEUTICALS INC. shareholders by shares voted on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.”, 2023-2024
#Asset manager % of shares outstanding
1Lazard 17.67%
2Avoro Capital Advisors LLC 6.50%
3State Street 6.16%
4Fidelity 5.91%
5BlackRock 3.64%
6GEODE CAPITAL MANAGEMENT, LLC 2.45%
7UBS 1.54%
8Capital Group 1.43%
9Slate Path Capital LP 1.32%
10MELLON INVESTMENTS Corp 1.20%

Reported ARROWHEAD PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ARROWHEAD PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock20,224,825 18.81%Form 13F, quarter ended March 31, 2024
Vanguard Group16,035,870 14.92%Form 13F, quarter ended March 31, 2024
State Street6,560,703 6.10%Form 13F, quarter ended March 31, 2024
FMR (Fidelity)5,759,830 5.36%Form 13F, quarter ended March 31, 2024
Christopher Anzalone3,715,048 3.46%Proxy statement (DEF 14A), proxy filed January 26, 2024
Geode Capital2,754,634 2.56%Form 13F, quarter ended March 31, 2024
Goldman Sachs1,823,578 1.70%Form 13F, quarter ended March 31, 2024
Morgan Stanley1,702,674 1.58%Form 13F, quarter ended March 31, 2024
Northern Trust1,300,649 1.21%Form 13F, quarter ended March 31, 2024
Norges Bank1,257,545 1.17%Form 13F, quarter ended March 31, 2024

Percentages above are of 107,500,000 shares outstanding, as reported by ARROWHEAD PHARMACEUTICALS INC. on its Form 10-Q dated December 31, 2023 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ARROWHEAD PHARMACEUTICALS INC.'s shareholder meeting held March 14, 2024, in the 2023-2024 proxy season, 293 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 2,979 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. ARROWHEAD PHARMACEUTICALS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION. — the reporting funds and managers cast 98% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARROWHEAD PHARMACEUTICALS INC.’s 10-Q dated December 31, 2023. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ARROWHEAD PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “ARROWHEAD PHARMACEUTICALS (ARWR) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/arrowhead-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.